Thank you to everyone who joined our Chief Technology Officer, Dr James Malone, to discuss trust and explainability in using AI in drug discovery. Describing how explainable AI can increase transparency in drug discovery, James presented data that compared the performance of our Retrieve to Explain (R2E) system against traditional approaches in predicting clinical trial outcomes. When utilising all data modalities, James shared that R2E demonstrated a higher relative success rate in identifying promising drug targets compared to industry-leading genetics-based methods. These performance improvements confirm R2E's potential to significantly impact the drug discovery process, particularly in the critical areas of target identification and clinical trial success prediction. 👉 Further information is available here: https://lnkd.in/eXeRpuni As the congress draws to a close, our thanks also goes to all the delegates who attended the Keynote Panel, or joined our expert team at our booth to discuss our proprietary pipeline, innovative industry collaborations and validated AI drug discovery technologies. If you were unable to attend BioTechX Europe and would like to speak with our team, contact us: bd@benevolent.ai #BioTechX
BenevolentAI
Biotechnology Research
London, Greater London 58,308 followers
Accelerate scientific breakthroughs with AI
About us
BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development. In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack treatment, our technology can increase the probability of success and reduce timelines. Our proprietary Benevolent PlatformTM is one of the industry's most established and validated AI drug discovery technologies. Expertise across Target Identification, Chemistry and Drug Repurposing enables us to deliver across the entire R&D lifecycle. We unite science and technology to serve patients with complex diseases – because it matters. BenevolentAI is headquartered in London, with our own state-of-the-art wet-labs in Cambridge, UK.
- Website
-
http://benevolent.com
External link for BenevolentAI
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- London, Greater London
- Type
- Public Company
- Founded
- 2013
- Specialties
- Artificial Intelligence, Drug Development, Machine Learning, Deep Learning, Big Data, Drug Discovery, Technology, Pharmaceuticals, and TechBio
Locations
-
Primary
Maple Street
4-8
London, Greater London W1T 5HD, GB
-
1 Dock 72 Way
7th Floor
Brooklyn, New York NY 11205, US
-
Babraham Hall, Babraham,
Cambridge , Cambridgeshire CB22 3AT, GB
Employees at BenevolentAI
-
April Gibson
User Experience Leader
-
Jeremy Sohn
Managing Partner, P74 Ventures & P74 Bio
-
Bastiaan Bergman
VP of AI at Benevolent AI | Leveraging AI to Drive Frontier Products and Push the Boundaries of Human Capabilities | Avid Kitesurfer
-
Jane McGuffog
VP Discovery, DMPK and Safety, Benevolent AI
Updates
-
In the UK alone, more than half a million people are affected by Crohn’s disease and ulcerative colitis. Alongside the physical symptoms of these IBD conditions, patients often report a profound impact on their mental health - with work, sleep and relationships severely affected. This week sees the release of a new IBD UK report, revealing that: • Quality of care has declined over the past five years. No IBD service in the UK is meeting the IBD standards for care or staffing. • People experience significant delays at every stage of interaction with the health system. • 1 in 7 patients are being diagnosed during an emergency hospital admission. There is an urgent need for clearer routes to diagnosis, reduced waiting times and improved standards of care to ensure people with Crohn’s disease and ulcerative colitis receive the treatment and support they need. The report’s findings and recommendations can be found here: https://lnkd.in/ecy-NuEW Information about our IBD asset, which has completed phase 1 studies, can be found here: https://lnkd.in/e3Pmmz-4
-
London Life Sciences Week, and Jefferies Healthcare Conference, is underway across the city. Our leadership team is attending a range of events throughout the week. To arrange to meet, contact us: investors@benevolent.ai #JefferiesHealthcare #LLSW2024 https://lnkd.in/ecVeWtrF
-
BenevolentAI reposted this
Join BenevolentAI and Rancho Biosciences for an informative discussion to learn how single-cell transcriptomics data at scale is helping to revolutionize drug discovery by providing deeper insights into cellular mechanisms. https://lnkd.in/gZt7PjrN In these presentations we will discuss: - The importance of high-quality data to produce meaningful insights and the robust workflows created to deliver analysis-ready single-cell transcriptomics datasets at scale - Introduction to BenevolentAI’s target discovery platform as illustrated by several cases studies that demonstrate its utility for mechanistic drug discovery. - How to prepare volumes of high-quality data for meaningful insights Learn how these innovative, AI-driven, disease agnostic approaches can transform your research, and lead to more effective, novel drug discovery outcomes more rapidly. #DrugDiscovery #SingleCellTranscriptomics #AIinHealthcare #Biotechnology #DataScience #PrecisionMedicine #ResearchInnovation #CellularMechanisms #BenevolentAI #RanchoBiosciences #HighQualityData #MechanisticInsights #PharmaceuticalResearch #HealthcareInnovation
Welcome! You are invited to join a webinar: Integrating Single-Cell Transcriptomics at Scale for Mechanistic Drug Discovery. After registering, you will receive a confirmation email about joining the webinar.
us02web.zoom.us
-
We are excited to be attending the BIO International Convention, 4-6 November, in Stockholm. 🚀 Identify and accelerate novel drug discoveries. Find out about our validated AI drug discovery technologies, industry-leading collaborations and proprietary pipeline that includes: 👉 Asset BEN-8744 for Ulcerative Colitis & Crohn’s Disease: Completed Phase I 👉 Asset BEN-28010 for Glioblastoma (GBM): Completed regulatory toxicology studies 👉 Asset BEN-34712 for Amyotrophic Lateral Sclerosis (ALS): Completed preclinical development To meet with our team, contact us: bd@benevolent.ai
-
Did you miss the Keynote Panel at BioTechX Europe that explored the benefits of AI in drug discovery? Panel chair Dr Ivan Griffin, our Co-Founder & Chief Business Officer, and Dr James Malone, Chief Technology Officer, were joined by: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD 📺 Catch the session in full now: https://lnkd.in/dbt4_Ybp #BioTechX
Keynote Panel: The benefits of AI within drug discovery
https://www.youtube.com/
-
Today, we announce the appointment of co-founder Kenneth Mulvany as Executive Chairman. We are also pleased to confirm the return of co-founder Michael Brennan as Chief Strategy and Financial Officer. Kenneth Mulvany comments: “When we founded BenevolentAI, our vision was to harness the power of AI to tackle healthcare's most pressing challenges. We have since developed one of the world's most advanced and validated AI drug discovery and development platforms, achieved the first FDA approval for an AI-identified drug, secured partnerships with global pharmaceutical leaders, and built a robust pipeline of potential first-in-class medicines for unmet medical needs. However, we have only scratched the surface of our platform's incredible potential..." 👉 Read more: https://lnkd.in/eBrWVsCH
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
benevolent.com
-
Our CEO, Dr Joerg Moeller, M.D., shares his expertise on the real-world value of generative AI as part of WSJ CEO Council: “The pharma and biotech industry still faces over a 90% failure rate in drug development, and 9,000 diseases lack effective treatments. By integrating data from a vast range of sources—from genetics to clinical trials across all disease areas—generative AI can help us uncover new insights, identify new drug targets and improve success rates while reducing timelines. Patient-driven disease modelling focuses on mechanisms driving tailored medicines, while AI’s agnostic approach helps us overcome challenges even top scientists face.” The feature is available in the print edition of The Wall Street Journal, alongside insights from: 👉 Ken Keller of Daiichi Sankyo US 👉 Brian Becker of RSM US LLP 👉 Revathi Advaithi of Flex #WSJCEOCouncil #CEOExcellence
-
This weekend, congress season continues apace with the UEG - United European Gastroenterology conference in Vienna. To hear about our novel target for ulcerative colitis and Crohn’s disease, BEN-8744, and discuss its potential, connect onsite with our VP of Clinical Development & Translational Medicine, Judit Molnar MD PhD, or contact our team: bd@benevolent.ai #UEGWeek
-
Today at BioTechX Europe, our Chief Technology Officer, Dr James Malone, will discuss "Building Trust and Explainability in using AI in Drug Discovery". James will describe how explainable AI can increase transparency in drug discovery, focusing on BenevolentAI's innovative R2E (Retrieve to Explain) system. He'll illustrate the capabilities of R2E, which combines AI-driven information retrieval with explainable predictions to enhance drug target identification. James will also present data comparing R2E's performance against traditional approaches in predicting clinical trial outcomes. More information is available here: https://lnkd.in/eXeRpuni If you're onsite in Basel, join us at 11.45 AM CET in Theatre 3. #BioTechX
BenevolentAI to present on explainable AI for drug discovery at BioTechX Europe 2024
benevolent.com